文献速递心外重症与机械循环支持

通过临床管理预防HeartMate II泵血栓:PREVENT多中心研究

PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study.
PubMed 文献 · J Heart Lung Transplant · 2016-11-16

PREVENT是一项前瞻性、多中心、单臂、非随机研究,纳入24个中心300例植入HeartMate II的患者,评估遵循PREVENT推荐(植入技术、抗凝策略、泵速管理)下的泵血栓发生率。结果显示3个月确认泵血栓率为2.9%,6个月为4.8%;完全遵循植入技术、肝素桥接和泵速≥9,000 RPM的患者6个月泵血栓风险显著更低(1.9% vs 8.9%,p<0.01)。

要点

  • 遵循PREVENT推荐与低确认泵血栓率相关。
  • 完全遵循者6个月泵血栓风险显著低于未完全遵循者。
  • 6个月复合风险(疑似血栓、溶血、缺血性卒中)也显著降低。

核心结论

  • 采用结构化手术植入技术和临床管理策略(PREVENT推荐)的所有组成部分与低确认泵血栓率相关。

研究设计与样本

  • 前瞻性、多中心、单臂、非随机研究,纳入24个中心300例植入HeartMate II的患者。

主要发现

  • 3个月确认泵血栓率为2.9%,6个月为4.8%。
  • 完全遵循植入技术、肝素桥接和泵速≥9,000 RPM者6个月泵血栓风险为1.9% vs 8.9%(p<0.01)。
  • 完全遵循者6个月复合风险(疑似血栓、溶血、缺血性卒中)为5.7% vs 17.7%(p<0.01)。

关键数值与推荐

  • 确认泵血栓定义为任何疑似泵血栓经视觉确认和/或独立评估者裁定。
  • adherence to key recommendations: 78% to surgical recommendations, 95% to heparin bridging, 79% to pump speeds ≥9,000 RPMs (92% >8,600 RPMs).

临床怎么用

  • 在HeartMate II植入患者中实施PREVENT推荐的植入技术、肝素桥接和泵速管理以降低泵血栓风险。

局限性

  • 单臂非随机设计,无法排除混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recommended structured clinical practices including implant technique, anti-coagulation strategy, and pump speed management (PREVENT [PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management] recommendations) were developed to address risk of early (<3 months) pump thrombosis (PT) risk with HeartMate II (HMII; St. Jude Medical, Inc. [Thoratec Corporation], Pleasanton, CA). We prospectively assessed the HMII PT rate in the current era when participating centers adhered to the PREVENT recommendations. METHODS: PREVENT was a prospective, multi-center, single-arm, non-randomized study of 300 patients implanted with HMII at 24 participating sites. Confirmed PT (any suspected PT confirmed visually and/or adjudicated by an independent assessor) was evaluated at 3 months (primary end-point) and at 6 months after implantation. RESULTS: The population included 83% men (age 57 years ± 13), 78% destination therapy, and 83% Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Profile 1-3. Primary end-point analysis showed a confirmed PT of 2.9% at 3 months and 4.8% at 6 months. Adherence to key recommendations included 78% to surgical recommendations, 95% to heparin bridging, and 79% to pump speeds ≥9,000 RPMs (92% >8,600 RPMs). Full adherence to implant techniques, heparin bridging, and pump speeds ≥9,000 RPMs resulted in a significantly lower risk of PT (1.9% vs 8.9%; p < 0.01) and lower composite risk of suspected thrombosis, hemolysis, and ischemic stroke (5.7% vs 17.7%; p < 0.01) at 6 months. CONCLUSIONS: Adoption of all components of a structured surgical implant technique and clinical management strategy (PREVENT recommendations) is associated with low rates of confirmed PT.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Maltais S, Kilic A, Nathan S, et al. PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. J Heart Lung Transplant. 2016. PMID: 27865732. doi:10.1016/j.healun.2016.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。